Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | RORC | P51449 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.38 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA7 | P43166 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.37 |
| ▸ | MPO | P05164 | 1/20 | 0.37 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16075540 | 0.85 | CYP1A2 (0.60) | CYP1A2CYP3A4CYP2C8CYP2C9CYP2C19 | |
| SCHEMBL21393518 | 0.83 | CYP1A2 (0.52) | CYP1A2CYP3A4CYP2C8CYP2C9CYP2C19 | |
| SCHEMBL21383167 | 0.81 | CYP1A2 (0.48) | CYP1A2CYP3A4CYP2C8CYP2C9CYP2C19 | |
| SCHEMBL23279451 | 0.81 | CYP1A2 (0.52) | CYP1A2CYP3A4CYP2C8CYP2C9CYP2C19 | |
| SCHEMBL27188138 | 0.80 | CYP1A2 (0.58) | CYP1A2CYP3A4CYP2C8CYP2C9CYP2C19 | |
| SCHEMBL16075537 | 0.80 | CYP1A2 (0.52) | CYP1A2CYP3A4CYP2C8CYP2C9CYP2C19 | |
| SCHEMBL16710476 | 0.80 | CYP1A2 (0.52) | CYP1A2CYP3A4CYP2C8CYP2C9CYP2C19 | |
| SCHEMBL16075536 | 0.80 | CYP1A2 (0.49) | CYP1A2CYP3A4CYP2C8CYP2C9CYP2C19 | |
| SCHEMBL23279413 | 0.79 | CYP1A2 (0.51) | CYP1A2CYP3A4CYP2C8CYP2C9CYP2C19 | |
| SCHEMBL22905459 | 0.79 | CYP1A2 (0.57) | CYP1A2CYP3A4CYP2C8CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240109843-A1 | BENZALDEHYDE COMPOUNDS WITH DIRECT POLYMER DESTABILIZING EFFECTS TO TREAT SICKLE CELL DISEASE | KING ABDULAZIZ UNIVERSITY (SA) | 2024-04-04 | — | — | US | disclosed |
| US-20220340531-A1 | AROMATIC ALDEHYDES WITH SUSTAINED AND ENHANCED IN VITRO AND IN VIVO PHARMACOLOGIC ACTIVITY TO TREAT SICKLE CELL DISEASE | VIRGINIA COMMONWEALTH UNIVERSITY | 2022-10-27 | — | — | US | disclosed |
| US-11401241-B2 | Aromatic aldehydes with sustained and enhanced in vitro and in vivo pharmacologic activity to treat sickle cell disease | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2022-08-02 | — | — | US | disclosed |
| US-11401241-B2 | Aromatic aldehydes with sustained and enhanced in vitro and in vivo pharmacologic activity to treat sickle cell disease | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2022-08-02 | — | — | US | disclosed |
| EP-3768264-A1 | AROMATIC ALDEHYDES WITH SUSTAINED AND ENHANCED IN VITRO AND IN VIVO PHARMACOLOGIC ACTIVITY TO TREAT SICKLE CELL DISEASE | Virginia Commonwealth University (US) | 2021-01-27 | — | — | EP | disclosed |
| US-20210002225-A1 | AROMATIC ALDEHYDES WITH SUSTAINED AND ENHANCED IN VITRO AND IN VIVO PHARMACOLOGIC ACTIVITY TO TREAT SICKLE CELL DISEASE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-01-07 | — | — | US | disclosed |
| US-20210002225-A1 | AROMATIC ALDEHYDES WITH SUSTAINED AND ENHANCED IN VITRO AND IN VIVO PHARMACOLOGIC ACTIVITY TO TREAT SICKLE CELL DISEASE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-01-07 | — | — | US | disclosed |
| WO-2019182938-A1 | AROMATIC ALDEHYDES WITH SUSTAINED AND ENHANCED IN VITRO AND IN VIVO PHARMACOLOGIC ACTIVITY TO TREAT SICKLE CELL DISEASE | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2019-09-26 | — | — | WO | disclosed |
| WO-2019182938-A1 | AROMATIC ALDEHYDES WITH SUSTAINED AND ENHANCED IN VITRO AND IN VIVO PHARMACOLOGIC ACTIVITY TO TREAT SICKLE CELL DISEASE | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2019-09-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220340531-A1 | AROMATIC ALDEHYDES WITH SUSTAINED AND ENHANCED IN VITRO AND IN VIVO PHARMACOLOGIC ACTIVITY TO TREAT SICKLE CELL DISEASE | HBG1, HBG2, HBB | CYP1A2 1548/4885CYP3A4 750/4885CYP2C8 674/4885 |
| US-20240109843-A1 | BENZALDEHYDE COMPOUNDS WITH DIRECT POLYMER DESTABILIZING EFFECTS TO TREAT SICKLE CELL DISEASE | HBG1, HBB, HBG2 | CYP1A2 4242/4885CYP3A4 3684/4885CYP2C8 3847/4885 |
| US-20210002225-A1 | AROMATIC ALDEHYDES WITH SUSTAINED AND ENHANCED IN VITRO AND IN VIVO PHARMACOLOGIC ACTIVITY TO TREAT SICKLE CELL DISEASE | HBG1, HBG2, HBB | CYP1A2 1548/4885CYP3A4 750/4885CYP2C8 674/4885 |
| US-11401241-B2 | Aromatic aldehydes with sustained and enhanced in vitro and in vivo pharmacologic activity to treat sickle cell disease | HBG1, HBG2, HBB | CYP1A2 1548/4885CYP3A4 750/4885CYP2C8 674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.